Center-Authored Papers

Filters: Author is Powell, Bayard L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou D-C et al..  2012.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations and additional chromosome abnormalities in relapse acute promyelocytic leukemia.. Blood. Abstract
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
P
Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH.  2012.  Phase 2 trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.. Haematologica. 97(5):739-742. Abstract
H
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M et al..  2009.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4754-9. Abstract
F
Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL et al..  2012.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
D
Mantha S, Goldman DA, Devlin SM, Lee J-W, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM et al..  2017.  Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.. Blood. Abstract
C
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A et al..  2017.  Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).. Journal of hematology & oncology. 10(1):131. Abstract
A
Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA et al..  2013.  Arsenic Trioxide in Front-line Therapy of Acute Promyelocytic Leukemia (C9710): Prognostic Significance of FLT3 Mutations and Complex Karyotype.. Leukemia & lymphoma. Abstract